Alzamend Neuro (ALZN) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing patented therapeutics for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD through two lead candidates: AL001 (ionic cocrystal lithium formulation) and ALZN002 (cell-based immunotherapy vaccine).

• AL001 targets cognitive and mood disorders, leveraging established lithium safety data, and has completed Phase IIA trials with positive topline results.

• ALZN002 is an autologous immunotherapy vaccine for Alzheimer's, currently in Phase I/IIA trials, aiming for a safer, longer-lasting effect than monoclonal antibodies.

• Pipeline expansion includes additional indications and delivery methods for AL001 and further clinical development for both candidates.

Financial performance and metrics

• Requires substantial additional funding to continue operations and clinical development; working capital needs depend on trial progress and regulatory milestones.

• Has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by the selling stockholder, except for potential proceeds from warrant exercises, which would be used for general working capital.

• Net proceeds from the sale of preferred shares are expected to be used for working capital and general corporate purposes.